Evidence map›Paper›PMID 31668389›Full record

ArticleMolecular metabolism2019

New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans.

Marie Mortreux, Ewout Foppen, Raphaël G Denis, Mireia Montaner, Nadim Kassis, Jessica Denom, Mylène Vincent, Frédéric Fumeron, Margaux Kujawski-Lafourcade, Fabrizio Andréelli and 6 more

Abstract read
In one paragraph

Article in Molecular metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Marie MortreuxUniversité de Paris, Paris, France; Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR8251, Paris, France.
Ewout FoppenUniversité de Paris, Paris, France; Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR8251, Paris, France.
Raphaël G DenisUniversité de Paris, Paris, France; Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR8251, Paris, France.
Mireia MontanerUniversité de Paris, Paris, France; Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR8251, Paris, France.
Nadim KassisUniversité de Paris, Paris, France; Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR8251, Paris, France.
Jessica DenomUniversité de Paris, Paris, France; Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR8251, Paris, France.
Mylène VincentUniversité de Paris, Paris, France; Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR8251, Paris, France.
Frédéric FumeronUniversité de Paris, Paris, France; Centre de Recherche des Cordeliers, INSERM UMR-S 1138, Paris, France.
Margaux Kujawski-LafourcadeUniversité de Paris, Paris, France.
Fabrizio AndréelliDepartment of Diabetology, Assistance publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, France; Institute of Cardiometabolism and Nutrition (ICAN), Pitié-Salpêtrière Hospital, Paris, France; Sorbonne Université, UMR_S 1269, Inserm, Paris, France.
Beverley BalkauCentre for research in Epidemiology and Population Health (CESP), INSERM, UMR-S 1018, University Paris-Sud, University Versailles Saint-Quentin, Villejuif, France.
Michel MarreUniversité de Paris, Paris, France; Centre de Recherche des Cordeliers, INSERM UMR-S 1138, Paris, France; Diabetology, Endocrinology, Nutrition, APHP - Bichat Hospital, Paris, France.
Ronan RousselUniversité de Paris, Paris, France; Centre de Recherche des Cordeliers, INSERM UMR-S 1138, Paris, France; Diabetology, Endocrinology, Nutrition, APHP - Bichat Hospital, Paris, France.
Christophe MagnanUniversité de Paris, Paris, France; Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR8251, Paris, France.
Hirac GurdenUniversité de Paris, Paris, France; Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR8251, Paris, France.
Stéphanie Migrenne-LiUniversité de Paris, Paris, France; Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR8251, Paris, France. Electronic address: stephanie.migrenne@univ-paris-diderot.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveProkineticin 2 (PROK2) is a hypothalamic neuropeptide that plays a critical role in the rhythmicity of physiological functions and inhibits food intake. PROK2 is also expressed in the main olfactory bulb (MOB) as an essential factor for neuro-and morphogenesis. Since the MOB was shown to be strongly involved in eating behavior, we hypothesized that PROK2 could be a new target in the regulation of food intake and energy homeostasis, through its effects in the MOB. We also asked whether PROK2 could be associated with the pathophysiology of obesity, the metabolic syndrome (MetS), and type 2 diabetes (T2D) in humans.

methodsWe assessed in wild type mice whether the expression of Prok2 in the MOB is dependent on the nutritional status. We measured the effect of human recombinant PROK2 (rPROK2) acute injection in the MOB on food intake and olfactory behavior. Then, using a lentivirus expressing Prok2-shRNA, we studied the effects of Prok2 underexpression in the MOB on feeding behavior and glucose metabolism. Metabolic parameters and meal pattern were determined using calorimetric cages. In vivo 2-deoxyglucose uptake measurements were performed in mice after intraperitoneally insulin injection. Plasmatic PROK2 dosages and genetic associations studies were carried out respectively on 148 and more than 4000 participants from the D.E.S.I.R. (Data from an Epidemiologic Study on the Insulin Resistance Syndrome) cohort.

resultsOur findings showed that fasting in mice reduced Prok2 expression in the MOB. Acute injection of rPROK2 in the MOB significantly decreased food intake whereas Prok2-shRNA injection resulted in a higher dietary consumption characterized by increased feeding frequency and decreased meal size. Additionally, Prok2 underexpression in the MOB induced insulin resistance compared to scrambled shRNA-injected mice. In the human D.E.S.I.R. cohort, we found a significantly lower mean concentration of plasma PROK2 in people with T2D than in those with normoglycemia. Interestingly, this decrease was no longer significant when adjusted for Body Mass Index (BMI) or calorie intake, suggesting that the association between plasma PROK2 and diabetes is mediated, at least partly, by BMI and feeding behavior in humans. Moreover, common Single Nucleotide Polymorphisms (SNPs) in PROK2 gene were genotyped and associated with incident T2D or impaired fasting glycemia (IFG), MetS, and obesity.

conclusionsOur data highlight PROK2 as a new target in the MOB that links olfaction with eating behavior and energy homeostasis. In humans, plasma PROK2 is negatively correlated with T2D, BMI, and energy intake, and PROK2 genetic variants are associated with incident hyperglycemia (T2D/IFG), the MetS and obesity.

Indexed as

Feeding BehaviorInsulin ResistanceAdultAgedAnimalsDiabetes Mellitus, Type 2EatingEnergy MetabolismFemaleGastrointestinal HormonesHumansMaleMiceMiddle AgedNeuropeptidesOlfactory BulbGastrointestinal HormonesNeuropeptidesPROK2 protein, humanProk2 protein, mouseRecombinant ProteinsRNA, Small InterferingFood intakeInsulin resistanceMain olfactory bulbMeal patternMetabolic syndromeProkineticin 2

Identifiers

PMID31668389
PMCPMC6812023

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.